Storys zum Thema Pharmakologie
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Technische Universität München
Nanoswitches for tumor targeting
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Video: https://www.youtube.com/watch?v=_xXV0mCke1g NEWS RELEASE Nanoswitches for tumor targeting TUM spin-off Plectonic develops antibody-based immunotherapies Plectonic Biotech, a spin-off of the Technical University of Munich (TUM), has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of ...
mehrbenfovir AG has reached another milestone by completing the first part of the Phase 1 trial testing transketolase inhibitor / benfo-oxythiamine (B-OT)
Darmstadt (ots) - benfovir AG, a German pharmaceutical company focused on developing small molecules against viral infections such as SARS-CoV-2, dengue and herpes virus, today announced that the first part of the Phase 1 clinical trial (BV-01-101/ EudraCT Number: 2021-005616-60.) designed to evaluate the safety, ...
mehrbenfovir Announces First Subjects Dosed in Phase 1 Clinical Trial of B-OT/ B-OT IS BEING DEVELOPED FOR THE TREATMENT OF VIRAL INFECTIONS
Darmstadt (ots) - benfovir AG has reached another major milestone by moving its first compound into clinical development with the start of a Phase 1 testing B-OT in healthy volunteers. benfovir AG, a German pharmaceutical biotechnology company focused on developing small molecules against viral infection such as ...
mehrTechnische Universität München
Overcoming resistance of pancreatic cancer to immunotherapies
Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37173 High resolution images: https://mediatum.ub.tum.de/1641984 NEWS RELEASE “Inflaming” cold tumors Overcoming resistance of pancreatic cancer to immunotherapies Pancreatic carcinoma is a ...
mehrUniversity of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients
Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...
mehr
New therapeutic approach against SARS-CoV-2 successfully tested
Pfungstadt (ots) - - Scientists at the Universities of Frankfurt a.M. and Kent (UK) have identified a metabolic pathway (pentose-phosphate pathway) that is crucial for the propagation of the SARS-CoV-2 virus in human cells. - The compound benfo-oxythiamine, an inhibitor of this metabolic pathway, has succeeded in blocking the replication of the SARS-CoV-2 virus in human cells. - Preclinical testing of this compound has ...
mehrCosmetics: Glucosides ensure increased bioavailability
C osmetics: Glucosides ensure increased bioavailability Glucosides eliminate the need for microplastics and provide increased bioavailability in cosmetic applications Freising/Germany, December 9, 2021 – Conventional active ingredients and fragrances in cosmetic products often evaporate shortly after application to the skin. Freising-based biotech company 4GENE has solved this problem by developing a special process ...
mehrThe New Era Biotechnology Co., Ltd.
The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)
mehrAlmirall delivers solid nine months 2021 results and tightens its upgraded guidance
Barcelona, Spain (ots/PRNewswire) - - Strong Core business performance with growth in Core Net Sales EUR601.7 MM (+6.2% year-on-year) and Core EBITDA reaching EUR164.2 MM, (+20.3% year-on-year) driven by positive contribution from Growth Drivers and a strong EU dermatology performance - Key Growth Drivers underpinning increase in Core Net Sales. Strong performance from ...
mehrCPhI worldwide: German probiotics company SYNformulas seeks partnerships to drive internationalization
mehr- 2
The start-up Eisbach Bio in the IZB near Munich receives 6.7 million euros from the Bavarian state government for the development of a COVID-19 therapeutics
Ein Dokumentmehr
CPhI worldwide: German probiotics company SYNformulas seeks partnerships to drive internationalization
Press release Combating intestinal complaints and allergies CPhI worldwide: German probiotics company SYNformulas seeks partnerships to drive internationalization - SYNformulas, leading probiotics supplier from Germany, will exhibit for the first time at the pharmaceutical trade fair CPhI worldwide in Milan - Focus ...
mehrNew Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics
mehrEleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates. Its recently expanded production ...
mehrEleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more state-of-the-art, 500 l single-use reactors from Sartorius Stedim Systems. The scale-up will enable Eleva to enter ...
mehrLebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic deramatitis in two Phase 3 trials
Barcelona (ots/PRNewswire) - - Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials - Safety profile consistent with prior lebrikizumab studies in atopic dermatitis Lebrikizumab led to significant improvements with ...
mehrePresentation of the results of the in-vitro study regarding the anti-proliferative and pro-apoptotic effects of Polyphenon® E (Veregen®) at the 31st German Skin Cancer Congress on 10 September 2021
Strausberg (ots) - Aresus Pharma GmbH, a company of DERMAGO Holding GmbH, announced today that the abstract "Inhibition of cell-proliferation and cell viability by Polyphenon E ® (Veregen®) in cutaneous SCC cell lines" has been accepted as an e-poster short presentation at the 31st German Skin Cancer Congress. In ...
mehr
- 2
COVID-19: Start-up Eisbach Bio at the IZB receives EUR 8 million government grant
Ein Dokumentmehr - 7
Biotech start-ups at the IZB close deals worth more than 140 million EUR in the first half of 2021
Ein Dokumentmehr - 2
Lindis Biotech develops immunotherapy against bladder cancer
Ein Dokumentmehr Semdor Pharma adds Global Pharmaceutical Executive Rolf Hoffmann to its Board of Directors
Cologne (ots) - 30-year pharma veteran Rolf Hoffmann, formerly senior global executive at Amgen and Eli Lilly, joins Semdor Pharma as investor and commercial expert. Semdor Pharma Group announced today that it has added Rolf Hoffmann, a seasoned global pharma executive and advisor, to its Board of Directors, as well as an investor in the company. Mr. Hoffmann ...
mehrHitachi Medical Systems Europe Holding AG
2Hitachi Medical Systems Europe (HMSE): The new "Plus" in human-centered open MRI is taking off at ECR 2021 with "SynergyDrive", the suite for streamlined workflow and high-speed exams
mehr- 2
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
mehr
Origenis founds biotech company Neuron23 in Silicon Valley together with star investor Kleiner Perkins
Ein DokumentmehrEuropean Association of E-Pharmacies (EAEP)
EAEP as a Driving Force and Think Tank: European Association of Online Pharmacies Repositions Itself
Brussels/Berlin (ots) - The leading association of European online pharmacies has a new board team, a new name and a new external image: Walter Hess, Head Germany in the Group Management of the Zur Rose Group and CEO of DocMorris N.V., is now president of the association and Stefan Feltens, CEO SHOP APOTHEKE EUROPE, ...
mehrEuropean Society for Medical Oncology (ESMO)
Launch of ESMO Virtual Plenaries Brings Rapid Access to Ground-Breaking Cancer Research
mehrTechnische Universität München
New synthetic peptides could attenuate atherosclerosis
Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36446/ NEWS RELEASE New synthetic peptides could attenuate atherosclerosis Synthetic “mini” receptors block atherosclerosis Atherosclerosis, a lipid-triggered chronic inflammatory disease of our arteries, is the main cause of strokes and ...
mehr- 3
World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools
Ein Dokumentmehr Merger: Newly-formed Semdor Pharma Group becomes one of Europe's leading pharmaceutical companies for narcotics and medical cannabis
mehr